Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med Starts Phase II Trial of FGFR Inhibitor in Mesothelioma Patients

publication date: Mar 31, 2020

Hutchison China MediTech (Chi-Med) started a China Phase II trial of HMPL-453, a novel small molecule inhibitor of fibroblast growth factor receptors (FGFR). Chi-Med says HMPL-453 is aimed at solid tumors. The trial is a single-arm, multi-center, open-label study, evaluating the efficacy, safety and pharmacokinetics of HMPL-453 in advanced malignant mesothelioma patients who have failed at least one line of systemic therapy. Chi-Med said the candidate showed better potency and kinase selectivity in pre-clinical trials than other drugs in its class. More details....

Stock Symbols: (NSDQ/AIM: HCM)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here